People · Operator
Named in public records as an officer, director or promoter · active 2019–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. | — | Biotechnology | Series D+ | $282.2M | $940.9M | 2019 |
| Escient Pharmaceuticals Inc | — | Biotechnology | Series C | $108.8M | $995.9M | 2020 |
| Codexis, Inc. | — | Biotechnology | Series C | $50.0M | $2.0B | 2019 |
Kathleen Glaub at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kathleen Glaub on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Hirth | 2 | 7 |
| David Smith | 1 | 42 |
| Andrew Schwab | 1 | 16 |
| Jack Nielsen | 1 | 13 |
| Peter Moldt | 1 | 6 |
| Jason Hafler | 1 | 6 |
| Kevin Raidy | 1 | 4 |
| John Fry | 1 | 4 |
| Thomas Baruch | 1 | 4 |
| Michael Yi | 1 | 4 |
| Lawrence Blatt | 1 | 3 |
| Marcus Boehm | 1 | 3 |
| Carole Neuchterlein | 1 | 3 |
| Kathleen Sereda Glaub | 1 | 3 |
| Robert Tjian | 1 | 3 |
| Dennis Wolf | 1 | 3 |
| Patrick Yang | 1 | 3 |
| Lesley Ann Calhoun | 1 | 2 |
| Bridget Ann Martell | 1 | 2 |
| Leonid Beigelman | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.